Compare Organon & Co. Common Stock (OGN) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ryanair Holdings plc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ryanair Holdings plc trades at $51.83 (market cap $26.41B). The key difference: Ryanair Holdings plc is far larger — about 7.3× Organon & Co. Common Stock's market cap, and Ryanair Holdings plc pays the higher dividend (1.69%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ryanair Holdings plc for 72 Days on average.
| OGN | RYAAY | |
|---|---|---|
Market Cap | $3.62B | $26.41B |
Volume | 2,892,999 | 2,266,391 |
Sector | Health | Industrials |
52-Week High | $13.81 | $73.82 |
52-Week Low | $5.70 | $51.33 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $11.04B | $23.47B |
Dividend Yield | 0.58% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
RYAAY trades at $51.33, down 3.15% amid bearish technical signals despite strong fundamentals. The stock shows robust profitability with 12.13% net margins and attractive valuation at 13.23 P/E. Recent earnings performance has been mixed with Q1 2026 beating expectations but Q2 2026 missing. Technical indicators signal bearish momentum with oversold RSI conditions, while analyst consensus remains positive with 64.71% buy ratings.
The outlook balances strong operational performance against near-term headwinds including fuel cost volatility and Boeing MAX 10 certification delays. Revenue growth trajectory and market share gains support long-term potential, though elevated oil prices and competitive pressures present significant risks. Current valuation levels offer entry opportunity for patient investors despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
